RxDoctor Payments Data

Yi Zhang, MD

Psychiatry · San Marcos, TXNPI 1831696863

Payments from drug & device makers

$542in general payments, 2019–2025

Across 17 payments — averaging $31.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$228
  • Stryker$154
  • Otsuka America Pharmaceutical, Inc.$70
  • Teva Pharmaceuticals USA, Inc.$37
  • AbbVie$20
  • Lundbeck LLC$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$542 in reported general payments places this provider in the 60th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$36,907
Medicare patients
50
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$18,078
Duloxetine Hcl52$1,235
Olanzapine26$740
Bupropion Hcl SrBupropion Hcl15$648
Oxcarbazepine11$536
Bupropion XlBupropion Hcl21$508
Gabapentin33$376
Lamotrigine26$337
Amitriptyline Hcl13$324
Quetiapine Fumarate52$309
Buspirone Hcl21$305
Clonazepam37$300
Venlafaxine Hcl ErVenlafaxine Hcl18$290
Trazodone Hcl43$277
Escitalopram Oxalate19$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$70$18,07812 claims
Lilly USA, LLCOlanzapine$14$74026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →